Runs immune-sequencing technology (clonoSEQ, T-Detect) to measure disease at the molecular level for diagnostics and drug discovery.
Runs immune-sequencing technology (clonoSEQ, T-Detect) to measure disease at the molecular level for diagnostics and drug discovery.
Bills per test: clonoSEQ checks for leftover cancer cells in blood cancers, and Medicare and other insurers pay a set fee, so test volume and coverage decisions matter most. A second line sells sequencing services and drug-discovery work to pharmaceutical partners, paid by fees and milestones.
Moat: narrow (IP / patents, data, installed base). Proprietary immune-sequencing database and an FDA-cleared MRD test create a data moat and switching costs.
Headquarters: Seattle, Washington, US · Founded: 2009 · Employees: 624
Size Adaptive Biotechnologies (ADPT) is a United States Health Care company (Biotechnology) with a market value of $4.61B, the 1235th largest of 3,085 United States companies the cockpit tracks. Shares closed at $28.46 on 18 Nov 2026.
Performance Over six months the shares gained 103.9%, against -0.3% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd highest of 21 in its peer set.
Growth Revenue grew 17.9% over the last twelve months (peer median -1.2%); the operating margin is -15.6% (peer median -35.0%).
Valuation It trades at 15.8× enterprise value to sales against a peer median of 12.7× (7th most expensive of 16).
Capital Return on invested capital runs 27.3 points below its cost of capital (15.1% WACC).
Short interest Short interest is 7.1% of the free float (30 Oct 2026).
Next results Next results expected around 16 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $298M | $277M | $179M | $170M | $185M |
| Revenue growth | — | +55% | +5% | -8% | — |
| Gross profit | $213M | $194M | $96.6M | $72.5M | $106M |
| EBITDA | -$31.1M | -$39.3M | -$134M | -$179M | -$170M |
| Net income | -$70.5M | -$59.5M | -$159M | -$225M | -$200M |
| Free cash flow | -$8.82M | -$48.9M | -$98.9M | -$167M | -$200M |
| Capital expenditure | $4.54M | $2.96M | $3.66M | $10.7M | $16.3M |
| Total debt | $409M | $210M | $223M | $229M | $233M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Adaptive Biotechnologies ADPT | $4.61B | +104% | +18% | -16% | 15.8× | n/a |
| Natera NTRA | $42.0B | +41% | +37% | -9% | 14.1× | n/a |
| Guardant Health GH | $19.6B | +26% | +42% | -39% | 15.9× | n/a |
| NeoGenomics NEO | $1.98B | +72% | +11% | -6% | 2.9× | n/a |
| Personalis PSNL | $1.62B | +88% | +17% | -157% | 18.2× | n/a |
| Tempus AI TEM | $11.6B | +39% | +37% | -18% | 8.2× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ADPT | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +16.5% | -7.7% | 2nd highest of 21 |
| 6-month return | +103.9% | -0.3% | 3rd highest of 21 |
| Distance from 52-week high | -11.6% | -33.1% | 2nd highest of 21 |
| Revenue growth (TTM) | +17.9% | -1.2% | 6th highest of 16 |
| Operating margin | -15.6% | -35.0% | 8th highest of 16 |
| EV / Sales | 15.8× | 12.7× | 7th most expensive of 16 |
| ROIC minus cost of capital | -27.3 pp | -9.8 pp | 4th lowest of 13 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Adaptive Biotechnologies ADPT | United States | $4.61B | +104% | +18% | -16% | 15.8× | n/a | n/a |
| Shanghai RAAS Blood Products 002252.SZ | China | $4.57B | -15% | -22% | 17% | 5.4× | n/a | n/a |
| Edgewise Therapeutics EWTX | United States | $4.53B | +26% | n/a | n/a | n/a | n/a | n/a |
| Changchun High-Tech Industry (Group) 000661.SZ | China | $4.52B | -13% | -18% | -1% | 2.8× | 32.4% | +7.1% |
| Dianthus Therapeutics DNTH | United States | $4.73B | -5% | -12% | -8,684% | 1,432.1× | n/a | n/a |
| Hangzhou Tigermed Consulting 3347.HK | Hong Kong | $4.75B | 0% | +22% | 10% | 4.8× | 25.4% | +15.6% |
| Cogent Biosciences COGT | United States | $4.84B | -16% | n/a | n/a | n/a | n/a | n/a |
| 3SBio 1530.HK | Hong Kong | $4.28B | -31% | +102% | 61% | 0.9× | n/a | n/a |
| Beijing Wantai Biological Pharmacy Enterprise 603392.SS | China | $4.20B | -43% | +8% | -35% | 12.7× | n/a | n/a |
| Chongqing Zhifei Biological Products 300122.SZ | China | $5.28B | -1% | -28% | -210% | 5.3× | -6.5% | -10.0% |
| Lin BioScience 6696.TWO | Taiwan | $3.98B | +305% | n/a | n/a | n/a | n/a | n/a |
| CRISPR Therapeutics CRSP | United States | $3.90B | -17% | -34% | -2,059% | 95.6× | n/a | n/a |
| Anthem Biosciences ANTHEM.NS | India | $5.51B | +16% | -1% | 35% | 24.9× | 36.9% | +26.2% |
| Caris Life Sciences CAI | United States | $5.59B | +24% | +61% | 13% | 5.0× | 18.2% | +61.5% |
| Tango Therapeutics TNGX | United States | $3.71B | +4% | -100% | n/a | n/a | n/a | n/a |
| JOINN Laboratories (China) 6127.HK | Hong Kong | $3.70B | +6% | +17% | -4% | 12.4× | n/a | n/a |
| Relay Therapeutics RLAY | United States | $3.65B | +27% | +24% | -3,095% | 273.1× | n/a | n/a |
| Scholar Rock SRRK | United States | $5.86B | -1% | n/a | -71,732% | 9,900.4× | n/a | n/a |
| AbCellera Biologics ABCL | United States | $3.60B | +141% | +92% | -298% | 43.4× | n/a | n/a |
| Disc Medicine IRON | United States | $3.55B | +16% | n/a | n/a | n/a | n/a | n/a |
| Arrowhead Pharmaceuticals ARWR | United States | $6.09B | -44% | -46% | -157% | 14.0× | n/a | n/a |